|
|
 |
|
Total Number of Holdings (excluding cash): 49
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
545,417 |
$80,972,607.82 |
7.68% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
271,929 |
$73,181,532.48 |
6.94% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
291,025 |
$72,401,199.50 |
6.87% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
63,996 |
$71,925,744.36 |
6.82% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
1,083,077 |
$70,064,251.13 |
6.65% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,262,137 |
$37,574,095.57 |
3.56% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
175,962 |
$37,391,925.00 |
3.55% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
68,104 |
$36,020,205.60 |
3.42% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Drug Retailers |
147,562 |
$35,487,185.38 |
3.37% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
43,336 |
$35,115,594.16 |
3.33% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
87,193 |
$34,281,671.81 |
3.25% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
1,221,374 |
$33,941,983.46 |
3.22% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
226,536 |
$33,219,239.04 |
3.15% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
208,993 |
$25,998,729.20 |
2.47% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
50,039 |
$24,917,920.83 |
2.36% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
102,177 |
$24,529,632.39 |
2.33% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
111,963 |
$23,630,910.78 |
2.24% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
257,491 |
$18,941,037.96 |
1.80% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
65,016 |
$18,253,892.16 |
1.73% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
314,245 |
$18,122,509.15 |
1.72% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
153,238 |
$16,597,207.78 |
1.57% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
26,323 |
$15,553,997.47 |
1.48% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
201,743 |
$13,234,340.80 |
1.26% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
99,068 |
$12,686,648.08 |
1.20% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
192,994 |
$12,473,202.22 |
1.18% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
80,491 |
$12,486,568.83 |
1.18% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
86,689 |
$12,165,067.37 |
1.15% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
255,950 |
$11,643,165.50 |
1.10% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
166,664 |
$11,468,149.84 |
1.09% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
155,837 |
$10,296,150.59 |
0.98% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
107,853 |
$9,791,973.87 |
0.93% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
154,289 |
$8,600,068.86 |
0.82% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
333,860 |
$8,002,624.20 |
0.76% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
49,532 |
$7,973,661.36 |
0.76% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
50,561 |
$7,378,872.34 |
0.70% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
79,971 |
$6,806,331.81 |
0.65% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
396,812 |
$6,765,644.60 |
0.64% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
23,231 |
$6,709,809.73 |
0.64% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
228,070 |
$6,627,714.20 |
0.63% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
160,478 |
$6,656,627.44 |
0.63% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
17,018 |
$5,977,742.68 |
0.57% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
51,071 |
$5,948,239.37 |
0.56% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
61,410 |
$5,356,180.20 |
0.51% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
189,358 |
$5,222,493.64 |
0.50% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
50,555 |
$5,031,739.15 |
0.48% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
172,337 |
$4,203,299.43 |
0.40% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
13,933 |
$3,623,973.30 |
0.34% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
84,638 |
$3,591,190.34 |
0.34% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
57,274 |
$3,248,008.54 |
0.31% |
| US Dollar |
$USD |
|
Other |
2,036,569 |
$2,036,569.49 |
0.19% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|